Medicinova, Inc. MNOV
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $8.33 (+377.6% upside)
Key Stats
- Today's Range
- $1.74 – $1.78
- 50-Day Range
- $1.28 – $1.85
- 52-Week Range
- $1.17 – $1.96
- Volume
- 39K shs
- Average Volume
- 47K shs
- Market Cap
- $88.11 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.36
- Price / Sales
- 95.72
Short Interest
- Short Interest
- 4.32%
- Days to Cover
- 40.92
Financials (TTM)
- Revenue
- $920,481
- Net Income
- $-10,753,049
- Net Margin
- -1168.20%
- Return on Equity
- -28.85%
- Debt-to-Equity
- —
About Medicinova, Inc.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Related Stocks
Compare head-to-head: MNOV vs LLY·MNOV vs JNJ·MNOV vs ABBV·MNOV vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.